Steven Cohen’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.26M Buy
+61,189
New +$1.43M ﹤0.01% 2677
2026
Q1
– Sell
-1,700,000
Closed -$33.8M – 3933
2025
Q4
$28.1M Sell
1,700,000
-819,535
-33% -$13.8M 0.03% 692
2025
Q3
$36.6M Buy
2,519,535
+305,588
+14% +$4.39M 0.06% 340
2025
Q2
$31M Buy
+2,213,947
New +$31.2M 0.06% 357
2025
Q1
– Sell
-548,739
Closed -$11.2M – 2147
2024
Q4
$11.2M Buy
548,739
+215,209
+65% +$5.51M 0.02% 654
2024
Q3
$9.7M Sell
333,530
-719,620
-68% -$17.8M 0.02% 653
2024
Q2
$24.5M Buy
+1,053,150
New +$20.2M 0.06% 352
2024
Q1
– Sell
-644,406
Closed -$13.8M – 2280
2023
Q4
$13.8M Buy
+644,406
New +$12.8M 0.03% 574
2023
Q3
– Sell
-223,471
Closed -$6.59M – 2550
2023
Q2
$6.59M Buy
+223,471
New +$6.28M 0.02% 727
2023
Q1
– Sell
-64,400
Closed -$1.79M – 2300
2022
Q4
$1.79M Sell
64,400
-568,600
-90% -$16.9M 0.01% 955
2022
Q3
$19.4M Buy
+633,000
New +$20.6M 0.08% 330

Other funds holding DNLI

Steven Cohen's DNLI Position: Q3 2026 in Review

Steven Cohen opened a new position in Denali Therapeutics (DNLI) in Q3 2026: 61,189 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #2677 among its holdings. This is a return to the name: Steven Cohen previously reported a position in DNLI as recently as Q4 2025.

Steven Cohen first reported a position in DNLI in Q3 2022 and has held it in 11 quarters since. The position peaked at $36.6M in Q3 2025. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Steven Cohen held 61,189 shares of Denali Therapeutics worth $1.26M as of Q3 2026.
  • Denali Therapeutics was a new Steven Cohen position in Q3 2026.
  • Denali Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #2677 holding.
  • Steven Cohen first reported a position in Denali Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • Steven Cohen's Denali Therapeutics position peaked at $36.6M in Q3 2025.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.